Background: The population of large parts of Africa, South America and travellers to these areas are at risk of yellow fever (YF) with a 50% mortality risk. Yellow fever vaccine (YFV) propagated in hens' eggs confers protection in 95% of the vaccinated. The rate of anaphylaxis for YFV ranges from 0.42 to 1.8/100,000 doses with most cases considered to be due to egg allergy. Egg allergy is a contraindication for the YFV. Nevertheless, the potential fatal sequelae from YF give the incentive to protect everyone at risk irrespective of their allergic status. Methods: Six subjects who had had a recent reaction to egg and who were travelling to endemic areas (3 adults and 3 children) underwent skin prick tests (SPT) with undiluted YFV and egg extract. Intradermal tests for YFV were undertaken at a 1:10 dilution. In 4 egg-allergic patients with a positive SPT to YFV, a 7-step desensitization protocol was used. A 2-step (10 + 90%) protocol was used in the 2 subjects with a negative YFV SPT. Premedication was not administered. Results: All 6 patients were successfully vaccinated. Four patients completed desensitization: 1 developed mild local erythema at the injection site, 1 had fleeting generalized urticaria with local erythema/angioedema and 2 did not experience any adverse reactions. Patients who received YFV in 2 steps developed no adverse reactions. Conclusions: We describe the successful administration of YFV in 6 egg-allergic patients. The Cambridge Allergy 7-step protocol allows for its safe administration in patients with positive SPT to YFV. A 2-step protocol can be used in patients with negative YFV SPT.

Weir E, Haider S: Yellow fever: readily preventable but difficult to treat. CMAJ 2004;170:1909-1910.
Yellow fever fact sheet. WHO (accessed July 21, 2012).
UK Health Protection Agency. Yellow Fever Fact Sheet. (accessed July 21, 2012).
Domingo C, Niedrig M: Safety of 17D derived yellow fever vaccines. Expert Opin Drug Saf 2009;8:211-221.
Sanofi Pasteur. YF-VAX Yellow fever vaccine package insert, 2010.
Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K: Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 1981;59:895-900.
Kelso JM, Greenhawt MJ, Li TJ, Nicklas RA, Bernstein DI, Blessing-Moore J, et al: Adverse Reactions to Vaccines Practice Parameter 2012. J Allergy Clin Immunol 2012;130:25-43.
Salisbury D, Ramsay M, Noakes K (eds): Yellow fever; in: Immunisation Against Infectious Disease. UK Department of Health Green Book, updated March 26, 2012, pp 443-454 (accessed July 13, 2012).
Sanofi Pasteur MSD Ltd: Stamaril package insert, 2010.
Khromava AY, Eidex RB, Weld LH, Kohl KS, Bradshaw RD, Chen RT, et al: Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 2005;23:3256-3263.
Active immunization; in Pickering LK, Baker CJ, Long SS, McMillan JA (eds): Red Book: 2006 Report of the Committee on Infectious Diseases, ed 27. Elk Grove Village, American Academy of Pediatrics, 2006, pp 446-448.
Munoz-Cano R, Sanchez-Lopez J, Bartra J, Valero A: Yellow fever vaccine and egg allergy: really a problem? Allergy 2010;65:533-534.
Kelso JM: Adverse reactions to vaccines for infectious diseases; in Adkinson NF, Bochner BS, Busse WW, Holgate ST, Lemanske RF, Simons FER (eds): Middleton's Allergy: Principles and Practice, ed 7. Philadelphia, Mosby, 2008, pp 1189-1204.
Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, Marano N, et al: Adverse event reports following yellow fever vaccination. Vaccine 2008;26:6077-6082.
Kelso JM, Mootrey GT, Tsai TF: Anaphylaxis from yellow fever vaccine. J Allergy Clin Immunol 1999;103:698-701.
Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P: General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002;57:45-51.
Barbaud A, Goncalo M, Bruynzeel D, Bircher A: Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reaction. Contact Derm 2001;45:321-328.
Clark AT, Skypala I, Leech SC, Ewan PW, Dugué P, Brathwaite N, et al: British Society for Allergy and Clinical Immunology guidelines for the management of egg allergy. Clin Exp Allergy 2010;40:1116-1129.
Caubet JC, Kondo Y, Urisu A, Nowak-Węgrzyn A: Molecular diagnosis of egg allergy. Curr Opin Allergy Clin Immunol 2011;11:210-215.
Poel L, Chen J, Penagos M: Food allergy epidemics - is it only a Western phenomenon? Curr Allergy Clin Immunol 2009;22:121-126.
Kung SJ: Food allergy in sub-Saharan Africa. J Aller Ther 2011;S3:002. DOI:10.4172/2155-6121.S3-002.
Roukens AH, Vossen AC, van Dissel JT, Vis-ser LG: Reduced intradermal test dose of yellow fever vaccine induces protective immunity in individuals with egg allergy. Vaccine 2009;27:2408-2409.
Charpin J, Vervloet D, Birnbaum J, Tafforeau M, Sentissi S: Yellow fever: desensitization to an anti-amaril 17D vaccine performed on a patient with anaphylaxis to eggs. Bull Acad Natl Med 1987;171:1001-1005.
Fritschea PJ, Helbling A, Ballmer-Webera BK: Vaccine hypersensitivity - update and overview. Swiss Med Wkly 2010;140:238-246.
James JM, Zeiger RS, Lester MR, Fasano MB, Gern JE, Mansfield LE, et al: Safe administration of influenza vaccine to patients with egg allergy. J Pediatr 1998;133:624-628.
Gagnon R, Primeau MN, Des Roches A, Lemire C, Kagan R, Carr S, et al: Safe vaccination of patients with egg allergy with an adjuvanted pandemic H1N1 vaccine. J Allergy Clin Immunol 2010;126:317-323.
Greenhawt MJ, Chernin AS, Howe L, Li JT, Sanders G: The safety of the H1N1 influenza A vaccine in egg allergic individuals. Ann Allergy Asthma Immunol 2010;105:387-393.
Kelso JM: Administration of influenza vaccines to patients with egg allergy. J Allergy Clin Immunol 2010;125:800-802.
Kelso JM, Cockrell GE, Helm RM, Burks AW: Common allergens in avian meats. J Allergy Clin Immunol 1999;104:202-204.
Liccardi G, Szépfalusi Z, Noschese P, Nentwich I, D'Amato M, D'Amato G: Allergy to chicken meat without sensitization to egg proteins: a case report. J Allergy Clin Immunol 1997;100:577-579.
Sakaguchi M, Nakayama T, Inouye S: Food allergy to gelatin in children with systemic immediate-type reactions, including anaphylaxis, to vaccines. J Allergy Clin Immunol 1996;98:1058-1061.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.